Summit Therapeutics Inc expected to post a loss of 7 cents a share - Earnings Preview

Summit Therapeutics

28/10/2024 13:08

* Summit Therapeutics Inc  SMMT.OQ   SMMT.O  is expected
to report
resultson October 30 for the period ending September 30 2024
    * 
    * ​LSEG's mean analyst estimate for Summit Therapeutics Inc
is for
a loss of 7 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 2 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Summit
Therapeutics Inc is $40.00​, above​ its last closing price
of $21.26. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Jan. 1 0001   -0.06       -0.06      -0.09     Missed  -45.2
 Mar. 31 0001  -0.06       -0.06      -0.06     Met     0
                                                        ​
 ​​                                                     
                                                        ​
 This summary was machine generated October 28 at 13:08 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)